Related references
Note: Only part of the references are listed.Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
V Subbiah et al.
ANNALS OF ONCOLOGY (2022)
Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview
Clotilde Sparano et al.
ENDOCRINE-RELATED CANCER (2021)
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
Christine Dierks et al.
THYROID (2021)
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Lori J. Wirth et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force
Keith C. Bible et al.
THYROID (2021)
Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: Results of the AcSe Pembrolizumab Study from Unicancer.
Sophie Leboulleux et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Molecular therapeutics for anaplastic thyroid cancer
Nikita Pozdeyev et al.
SEMINARS IN CANCER BIOLOGY (2020)
Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib
Laura Leroy et al.
THYROID (2020)
Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).
Maria E. Cabanillas et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
PD-1 Blockade in Anaplastic Thyroid Carcinoma
Jaume Capdevila et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors
Maria E. Cabanillas et al.
THYROID (2020)
Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases
Bin Xu et al.
THYROID (2020)
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
Dora Dias-Santagata et al.
THYROID (2020)
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019
Anastasios Maniakas et al.
JAMA ONCOLOGY (2020)
Larotrectinib treatment of advanced TRK fusion thyroid cancer
M. E. Cabanillas et al.
ANNALS OF ONCOLOGY (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Diagnosis and Management of Anaplastic Thyroid Cancer
Ashish Chintakuntlawar et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2019)
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma
Jennifer R. Wang et al.
THYROID (2019)
Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer
Seong-Keun Yoo et al.
NATURE COMMUNICATIONS (2019)
A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer
Ashish V. Chintakuntlawar et al.
THYROID (2019)
A Phase II study of the safety and efficacy oflenvatinib in patients with advanced thyroidcancer
Shunji Takahashi et al.
FUTURE ONCOLOGY (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC
Gnana P. Krishnamoorthy et al.
CANCER DISCOVERY (2019)
Hypofractionated Radiotherapy for Anaplastic Thyroid Carcinoma: 15 Years of Experience in a Single Institution
Noriyoshi Takahashi et al.
EUROPEAN THYROID JOURNAL (2019)
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
Glenn J. Hanna et al.
CLINICAL CANCER RESEARCH (2018)
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Nikita Pozdeyev et al.
CLINICAL CANCER RESEARCH (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical and molecular single-institution study
Audrey Deeken-Draisey et al.
HUMAN PATHOLOGY (2018)
Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers
Jeffrey A. Knauf et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Treatment outcomes of radiotherapy for anaplastic thyroid cancer
Jong Won Park et al.
RADIATION ONCOLOGY JOURNAL (2018)
Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base
Todd A. Pezzi et al.
CANCER (2017)
Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer
Naiyarat Prasongsook et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study
Ashish V. Chintakuntlawar et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases
Benjamin Bonhomme et al.
THYROID (2017)
Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma
Sarika N. Rao et al.
THYROID (2017)
NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma
Vera Tiedje et al.
ONCOTARGET (2017)
Lenvatinib for Anaplastic Thyroid Cancer
Makoto Tahara et al.
FRONTIERS IN ONCOLOGY (2017)
The role of surgery in anaplastic thyroid cancer: A systematic review
Shirley Hu et al.
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2017)
Histopathological analysis of anaplastic thyroid carcinoma cases with long-term survival: A report from the Anaplastic Thyroid Carcinoma Research Consortium of Japan
Mitsuyoshi Hirokawa et al.
ENDOCRINE JOURNAL (2016)
Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival
Scott M. Glaser et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Inigo Lancia et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Recurrence and Survival After Gross Total Removal of Resectable Undifferentiated or Poorly Differentiated Thyroid Carcinoma
Doh Young Lee et al.
THYROID (2016)
Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing
John W. Kunstman et al.
HUMAN MOLECULAR GENETICS (2015)
Personalized Therapy in Patients With Anaplastic Thyroid Cancer: Targeting Genetic and Epigenetic Alterations
Neal Smith et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Undifferentiated (anaplastic) thyroid carcinoma: Practical immunohistochemistry and cytologic look-alikes
Ian Talbott et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2015)
Aggressive Palliation and Survival in Anaplastic Thyroid Carcinoma
Yuval Nachalon et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2015)
Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma
Julie A. Sosa et al.
THYROID (2014)
A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
S. M. Lim et al.
ANNALS OF ONCOLOGY (2013)
Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial
R. C. Smallridge et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
Panayiotis Savvides et al.
THYROID (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
Keith C. Bible et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Prognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 Patients
Iwao Sugitani et al.
WORLD JOURNAL OF SURGERY (2012)
A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer
Huan T. Ha et al.
THYROID (2010)
Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1
Julio C. Ricarte-Filho et al.
CANCER RESEARCH (2009)
Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2008)
Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens
Yongjin Wang et al.
CANCER (2006)
Anaplastic thyroid carcinoma - Treatment outcome and prognostic factors
E Kebebew et al.
CANCER (2005)
Neutrophilia associated with anaplastic carcinoma of the thyroid: Production of macrophage colony-stimulating factor (M-CSF) and interleukin-6
T Sato et al.
THYROID (2000)
Share Paper
